JP2024543973A - ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト - Google Patents
ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト Download PDFInfo
- Publication number
- JP2024543973A JP2024543973A JP2024532491A JP2024532491A JP2024543973A JP 2024543973 A JP2024543973 A JP 2024543973A JP 2024532491 A JP2024532491 A JP 2024532491A JP 2024532491 A JP2024532491 A JP 2024532491A JP 2024543973 A JP2024543973 A JP 2024543973A
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- acceptable salt
- ceutically acceptable
- compound according
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284750P | 2021-12-01 | 2021-12-01 | |
| US63/284,750 | 2021-12-01 | ||
| PCT/US2022/051493 WO2023102100A1 (en) | 2021-12-01 | 2022-12-01 | Antagonists of the muscarinic acetylcholine receptor m4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543973A true JP2024543973A (ja) | 2024-11-26 |
| JP2024543973A5 JP2024543973A5 (cg-RX-API-DMAC10.html) | 2025-12-08 |
Family
ID=84943708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532491A Pending JP2024543973A (ja) | 2021-12-01 | 2022-12-01 | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250145595A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4441046A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024543973A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240112343A (cg-RX-API-DMAC10.html) |
| CN (2) | CN116669737A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022400780A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3241298A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL313219A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024006718A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023102100A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3651762B1 (en) | 2017-07-12 | 2024-07-03 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| JP7270989B2 (ja) | 2017-10-20 | 2023-05-11 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| US12319701B2 (en) | 2019-10-04 | 2025-06-03 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| JP2024500880A (ja) * | 2020-12-22 | 2024-01-10 | ヴァンダービルト ユニヴァーシティ | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| WO2022261427A1 (en) | 2021-06-11 | 2022-12-15 | Vanderbilt University | (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102474326B1 (ko) * | 2016-06-22 | 2022-12-05 | 반더빌트유니버시티 | 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제 |
| AU2018313802A1 (en) * | 2017-08-08 | 2020-02-20 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| JP7270989B2 (ja) * | 2017-10-20 | 2023-05-11 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| WO2021119254A1 (en) * | 2019-12-10 | 2021-06-17 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| US20230183219A1 (en) * | 2020-04-24 | 2023-06-15 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| CA3180717A1 (en) * | 2020-04-24 | 2021-10-28 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
-
2021
- 2021-12-22 CN CN202180087480.8A patent/CN116669737A/zh active Pending
-
2022
- 2022-12-01 CN CN202280088712.6A patent/CN118541365A/zh active Pending
- 2022-12-01 IL IL313219A patent/IL313219A/en unknown
- 2022-12-01 MX MX2024006718A patent/MX2024006718A/es unknown
- 2022-12-01 US US18/715,048 patent/US20250145595A1/en active Pending
- 2022-12-01 JP JP2024532491A patent/JP2024543973A/ja active Pending
- 2022-12-01 WO PCT/US2022/051493 patent/WO2023102100A1/en not_active Ceased
- 2022-12-01 EP EP22843543.4A patent/EP4441046A1/en active Pending
- 2022-12-01 CA CA3241298A patent/CA3241298A1/en active Pending
- 2022-12-01 AU AU2022400780A patent/AU2022400780A1/en active Pending
- 2022-12-01 KR KR1020247021498A patent/KR20240112343A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240112343A (ko) | 2024-07-18 |
| AU2022400780A1 (en) | 2024-06-20 |
| CA3241298A1 (en) | 2023-06-08 |
| US20250145595A1 (en) | 2025-05-08 |
| CN118541365A (zh) | 2024-08-23 |
| CN116669737A (zh) | 2023-08-29 |
| WO2023102100A1 (en) | 2023-06-08 |
| MX2024006718A (es) | 2024-08-09 |
| EP4441046A1 (en) | 2024-10-09 |
| IL313219A (en) | 2024-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102776114B1 (ko) | 무스카린성 아세틸콜린 수용체 m4의 길항제 | |
| EP4267569B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| US20250145595A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| JP7572734B2 (ja) | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト | |
| AU2021261002A1 (en) | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 | |
| JP2023522959A (ja) | ムスカリンアセチルコリン受容体ｍ４のアンタゴニストとしての縮合置換ヒドロピロール | |
| WO2022216655A1 (en) | N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders | |
| US20230150986A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| AU2021381350A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| WO2022212819A1 (en) | Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4 | |
| WO2022261427A1 (en) | (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders | |
| WO2022036177A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| HK40121280A (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| HK40115503A (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| HK40097532A (en) | Antagonists of the muscarinic acetylcholine receptor m4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251128 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251128 |